Use and management of laboratory data is assessed by monitoring ease of access and retrieval of patient data, as well as laboratory quality indicators like turnaround time.
Modeling approaches can suggest transmission modalities to account for case patterns, but determination of human-to-human transmission requires detailed field epidemiologic investigations in which human, animal, and environmental exposures as well as clinical and laboratory data are assessed and interpreted.
Table 1 Modified Alvarado Scale Manifestations Value Migration of pain 1 Symptoms Anorexia 1 Nausea and/or vomiting 1 Signs Right lower quadrant tenderness 2 Rebound 1 Elevated temperature 1 Laboratory values Leukocytosis 2 Total points 9 Data were assessed by SPSS version 16, and a p value <0.05 was considered significant.
The quality of microarray data was assessed with two approaches used as a standard in our laboratory.
When pharmacokinetic data are assessed, it is necessary to differentiate between true patient population differences and differences in accuracy between assay methods or laboratories.
A further issue in summarizing data is assessing reliability across both different analytical methods and different laboratories.
Prospectively collected clinical and laboratory data were used for assessing organ dysfunction, systemic inflammatory response, and sepsis.
We also conducted additional analyses on a subgroup of RA patients, in whom laboratory data were available, to assess whether the severity of RA affects the risk of fracture, and observed an increased risk associated with positive RF and elevated acute phase reactants, although it was not statistically significant.
Demographic, clinical, and ICU laboratory data were prospectively collected; serum sodium was assessed an average of three times per day.
The completeness and quality of laboratory data was successfully assessed by matching the hospital admission code with data obtained by clinical charts.
